©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2024; 15(9): 1837-1841
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1837
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1837
MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease
Ashraf Al Madhoun, Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman 15400, Kuwait
Author contributions: Al Madhoun A designed the overall concept, reviewed the literature, and wrote and edited the manuscript.
Supported by the Kuwait Foundation for the Advancement of Sciences and Dasman Diabetes Institute , Kuwait, No. RACB-2021-007.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Ashraf Al Madhoun, PhD, Academic Research, Senior Scientist, Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Jassim AlBahar Street, Dasman 15400, Kuwait. ashraf.madhoun@dasmainstitute.org
Received: March 24, 2024
Revised: May 20, 2024
Accepted: June 17, 2024
Published online: September 15, 2024
Processing time: 156 Days and 1.4 Hours
Revised: May 20, 2024
Accepted: June 17, 2024
Published online: September 15, 2024
Processing time: 156 Days and 1.4 Hours
Core Tip
Core Tip: Wu et al identified microRNA-630 as a promising candidate for the management of diabetic kidney disease, exerting its protective effects through the regulation of toll-like receptor 4-mediated inflammatory pathways. Further research elucidating the precise molecular mechanisms underlying microRNA-630’s actions and its therapeutic potential is warranted, with the ultimate goal of developing targeted interventions to alleviate the burden of diabetic kidney disease and improve patient outcomes.